GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women among the most common users.

Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

Fact checked by Nick Blackmer With anti-obesity medications like Ozempic, Wegovy, and Zepbound exploding in popularity in recent years, there’s no shortage of chatter about surprising side effects, such as “Ozempic face” and “Ozempic butt.

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in blood-fat levels and weight gain in previous users of obesity drugs.

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Everyone is allowed to have their own opinion. But it’s important for me to own my own narrative and tell my own story.”

As Eli Lilly and Novo Nordisk have been battling it out to gain market share of the growing GLP-1 weight loss market, one demographic has been seen as increasingly important: cash-pay customers. These individuals,

Older adults with diabetes using GLP-1 receptor agonist medications may face increased risk of serious eye conditions, study suggests.